ArticleFrontiers in medicine2024
Prescribing practices of corticosteroids in outpatient dermatology department of Injibara General Hospital, north-West Ethiopia, 2024.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Corticosteroids are among the most frequently prescribed drugs in the world because they are extremely effective for the relief of symptoms of many inflammatory and immune disorders and other conditions. Corticosteroids have been a mainstay of pharmacotherapy in dermatological practice. Objective: This study aimed to assess prescribing practices of corticosteroids in outpatient dermatology department of Injibara General Hospital, North-West Ethiopia, 2024. Method: A facility-based retrospective cross-sectional study was conducted from September 1 to September 10, 2024, with 422 patient prescriptions issued at the dermatology outpatient department of Injibara General Hospital containing at least one corticosteroid medicine. All patient prescriptions dispensed from the dermatology outpatient department from April to August 2024 containing at least one corticosteroid medicine were included. A structured data collection tool was used to collect data, and Statistical Package for Social Science version 27.1 was used for data analysis. The study population was characterized through descriptive analysis. Results: Female patients accounted 54.2% of the cases recorded, and the most common age group was between 21 and 30 years (26.5%). Atopic dermatitis (15.4%) was the most common skin disorder, followed by papular urticaria (9.97%) and seborrheic dermatitis (8.9%) for which corticosteroids were prescribed. Topical corticosteroids were the most commonly prescribed medications, accounting for 94.1%. The percentage of corticosteroids prescribed by generic name was 82.4%. We found that the percentage of topical corticosteroid prescriptions in fixed drug combinations and extemporaneous prescription was 4.4 and 1.2%, respectively. Mometasone furoate was the most commonly prescribed (34.6%), followed by clobetasol propionate (26.7%). Ointments (53%) followed by creams (40.6%) were the most common formulations of topical corticosteroids issued. In the present study, moderate potency TCS were most commonly prescribed (32.3%), followed by high potency (28.3%), and super high potency (27.6%), respectively. Conclusion: From this study, it can be concluded that atopic dermatitis is the most common skin disease observed in the studied dermatology outpatient where the corticosteroid was indicated. Mometasone furoate and clobetasol propionate were the two most commonly prescribed agents. Prescribing practice of high potent and very high potent topical corticosteroids was found to be considerably high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.